COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #44 of 230
5/28 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gianfrancesco et al., Annals of the Rheumatic Diseases, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871 (Peer Reviewed)
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Source   PDF   Share   Tweet
Analysis of rheumatic disease patients showing no significant association between antimalarial therapy and hospitalisation, OR=0.94 [0.57-1.57], p=0.82 after adjustments.

Gianfrancesco et al., 5/28/2020, retrospective, database analysis, multiple countries, multiple regions, peer-reviewed, 28 authors.
risk of hospitalization, 3.3% lower, RR 0.97, p = 0.82, treatment 58 of 130 (44.6%), control 219 of 470 (46.6%), odds ratio converted to relative risk.
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.